NEW DELHI: Pune-based Serigen Mediproducts, a pioneering biomedical products manufacturer, has successfully raised ₹10 crores in a funding round led by IAN Alpha Fund and Colossa Ventures. This investment round also saw participation from existing and new angel investors. The newly acquired funds will be pivotal in advancing Serigen’s mission to revolutionize regenerative medicine.
Serigen Mediproducts, recognized for its innovative use of silk proteins in tissue regeneration, has developed three cutting-edge products: Serioss, an osteoconductive bone void filler; Seriderm, an absorbent wound dressing designed to accelerate wound healing; and Serimat, a silk protein mesh used in reconstructive surgeries, including breast reconstruction and dural repair.
These products offer significant advancements in medical care, harnessing the unique properties of silk protein to enhance patient outcomes in both wound care and surgical procedures. The company, which is part of the BioAngels portfolio, aligns with the broader vision of advancing biotechnology innovations.
Serigen has already received accolades for its groundbreaking work, including winning the Poster Pitch at the Orthopaedic Research Society’s Business Innovation Competition in the USA earlier this year. Additionally, Serigen has secured prestigious grants such as the DBT BIRAC BIG, SBIRI, and BIPP.
Expressing her gratitude, Anuya Nisal, Founder and CEO of Serigen Mediproducts, stated, “We
NEW DELHI: Pune-based Serigen Mediproducts, a pioneering biomedical products manufacturer, has successfully raised ₹10 crores in a funding round led by IAN Alpha Fund and Colossa Ventures. This investment round also saw participation from existing and new angel investors. The newly acquired funds will be pivotal in advancing Serigen’s mission to revolutionize regenerative medicine.
Serigen Mediproducts, recognized for its innovative use of silk proteins in tissue regeneration, has developed three cutting-edge products: Serioss, an osteoconductive bone void filler; Seriderm, an absorbent wound dressing designed to accelerate wound healing; and Serimat, a silk protein mesh used in reconstructive surgeries, including breast reconstruction and dural repair.
These products offer significant advancements in medical care, harnessing the unique properties of silk protein to enhance patient outcomes in both wound care and surgical procedures. The company, which is part of the BioAngels portfolio, aligns with the broader vision of advancing biotechnology innovations.
Serigen has already received accolades for its groundbreaking work, including winning the Poster Pitch at the Orthopaedic Research Society’s Business Innovation Competition in the USA earlier this year. Additionally, Serigen has secured prestigious grants such as the DBT BIRAC BIG, SBIRI, and BIPP.
Expressing her gratitude, Anuya Nisal, Founder and CEO of Serigen Mediproducts, stated, “We are delighted to welcome new institutional investors like IAN Alpha Fund in this round of funding and are grateful for the support from our existing and incoming angel investors and Colossa Ventures. The proceeds from this funding will be directed towards the completion of clinical trials, obtaining Indian and global regulatory approvals, accelerating sales and marketing efforts, and strengthening our team.”
Sarika Saxena, Managing Partner of IAN Alpha Fund, shared her enthusiasm about the investment, stating, “Serigen reflects IAN Alpha Fund’s thesis of investing in innovation and solving real problems. We look forward to working with the founders and supporting their vision of building a globally acclaimed company.”
Ashu Suyash, Founder and CEO of Colossa Ventures, emphasized the importance of Serigen’s work, adding, “Their innovative approach to leveraging silk proteins for critical care solutions aligns with our mission to back women-led ventures poised for scalable growth. We are excited to see how Serigen’s products will transform patient care and set new standards in
the medical field.”
